Trial Information

Summary: Phase II; Second Line Treatment

Open Label, Single Arm Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of CP-675,206 in Patients with Advanced Refractory and/or Relapsed Melanoma.
Prior 1st line must contain interleukin-2, dacarbazine and or temozolamide with at least 1 cycle at full dose. 30 day washout period since previous treatment. ECOG 0-1. No ocular melanoma or brain metastases.

Contact:

Cathy Spears, RN, Director
American Health Network of Indiana LLC, Oncology Division
St. Francis Clinical Research
1500 Albany St., Suite 1001
Beech Grove, IN 46107
Telephone: 317-782-7819
Fax: 317-782-7828
Email:

Profile Page: American Health Network of Indiana LLC, Oncology Division, Beech Grove, IN

If you would like to learn more about participating in this study, please send an e-mail message using the form below.

*Subject:

Name:

Address:

City:

State:

*Zip:

*Country:

Phone:

*Email address:

Message:

Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 5:45:57 AM


Back to Centerwatch Trial Listing by Location


Additional resources
in this illness area

Copyright © 1995 - 2008, CenterWatch
All Rights Reserved

This site was developed in association with Illumina Interactive, Boston, MA